Plus, news about Boundless Bio, Pelage, Actuate Therapeutics and Mersana Therapeutics:
Kyverna Therapeutics touts early safety of CAR-T therapy: The biotech said the first 36 patients with autoimmune disease who were treated with KYV-101 had no instances of severe immune effector cell-associated neurotoxicity syndrome (ICANS) or grade 3 or higher cytokine release syndrome. The safety of CAR-Ts is under scrutiny after Cabaletta Bio said last week that grade 4 ICANS occurred in a lupus patient treated with its therapy. — Ayisha Sharma
Evotec’s partnership with Bristol Myers Squibb pays off: The company pulled in $75 million worth of performance-based and program-based payments as part of a deal signed in 2018. According to the agreement, Bristol Myers and Evotec are developing molecular glue degraders using Evotec’s multi-omics screening and analytics capabilities with Bristol Myers’ cereblon E3 ligase modulators. — Katherine Lewin
Boundless Bio shrinks workforce: Five months after its $100 million
